Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Operating Expenses of $7.0 million for Q4 2025, up 281.73% on a QoQ basis from $1.8 million in Q3 2025, and up 2454.32% year-over-year from $275613.0 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Operating Expenses history runs 2 years deep, the most recent figure standing at $7.0 million for Q4 2025.
- Quarterly Operating Expenses rose 2454.32% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.9 million (up 834.25% YoY) and the FY2025 annual result came in at $11.9 million, up 834.25% from the prior year.
- Operating Expenses was $7.0 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $1.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $7.0 million in Q4 2025 and bottomed at $271726.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 455.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | 7.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.04 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 364,368.00 |
| Dec 31, 2024 | 275,613.00 |
| Sep 30, 2024 | 299,999.00 |
| Jun 30, 2024 | 427,757.00 |
| Mar 31, 2024 | 271,726.00 |